These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34531065)

  • 41. Changes to medicare part D: who benefits?
    DeMartino JK
    J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S4-6. PubMed ID: 20947723
    [No Abstract]   [Full Text] [Related]  

  • 42. Medicare Part D's effect on the under- and overuse of medications: a systematic review.
    Polinski JM; Donohue JM; Kilabuk E; Shrank WH
    J Am Geriatr Soc; 2011 Oct; 59(10):1922-33. PubMed ID: 21806563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medicare Part D and quality of prescription medication use in older adults.
    Lau DT; Briesacher BA; Touchette DR; Stubbings J; Ng JH
    Drugs Aging; 2011 Oct; 28(10):797-807. PubMed ID: 21970307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Access to and use of $4 generic programs in Medicare.
    Zhang Y; Gellad WF; Zhou L; Lin YJ; Lave JR
    J Gen Intern Med; 2012 Oct; 27(10):1251-7. PubMed ID: 22311333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
    Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased Cost With Use of Brand-Name Bowel Preparation by Patients With Medicare Part D From 2013 to 2015.
    Read AJ; Vijan S; Waljee AK; Saini SD
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2806-2807. PubMed ID: 30880272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
    Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
    BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 53. Use and spending on antineoplastic therapy for Medicare beneficiaries with cancer.
    Davidoff AJ; Shaffer T; Erten MZ; Shoemaker JS; Zuckerman IH; Pandya N; Stuart BC; Bryant-Comstock LG; Shenolikar R
    Med Care; 2013 Apr; 51(4):351-60. PubMed ID: 23222498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anticipatory Behavior in Response to Medicare Part D's Coverage Gap.
    Kaplan CM; Zhang Y
    Health Econ; 2017 Mar; 26(3):338-351. PubMed ID: 26749399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medicare Part D's Effects on Drug Utilization and Out-of-Pocket Costs: A Systematic Review.
    Park YJ; Martin EG
    Health Serv Res; 2017 Oct; 52(5):1685-1728. PubMed ID: 27480577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medicare Part D's effects on elderly patients' drug costs and utilization.
    Ketcham JD; Simon KI
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP14-22. PubMed ID: 18991476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries.
    Thatcher EE; Vanwert EM; Erickson SR
    J Pharm Pract; 2013 Jun; 26(3):248-52. PubMed ID: 23178417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmaceuticals and medical devices: Medicare Part D.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2014 Dec; ():1-31. PubMed ID: 25771554
    [No Abstract]   [Full Text] [Related]  

  • 59. New Math on Drug Cost-Effectiveness.
    Bach PB
    N Engl J Med; 2015 Nov; 373(19):1797-9. PubMed ID: 26535510
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmaceuticals and medical devices: cost savings.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.